David E. Lazar - 13 Feb 2026 Form 4 Insider Report for MAINZ BIOMED N.V. (MYNZ)

Reporting relationship: Director
Issuer ticker: MYNZ
Reported as of: 13 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2026, 10:13:06 UTC
Prior SEC filing: 05 Jan 2026
Next SEC filing: 24 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ David E. Lazar

Key filing fact

David E. Lazar filed Form 4 for MAINZ BIOMED N.V. (MYNZ) on 03 Mar 2026.

Key facts

This page summarizes David E. Lazar's Form 4 filing for MAINZ BIOMED N.V. (MYNZ).
3 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 03 Mar 2026, 10:13.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001932843 Primary reporting owner

Lazar David E.

Relationship: Director
Address: 44, TOWER 100, THE TOWERS, WINSTON CHURCHILL, PAITILLA, PANAMA CITY, PANAMA
Signature: /s/ David E. Lazar
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MYNZ holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 0
Date: 13 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MYNZ transaction Derivative

Series A Preferred Shares

Award

Transaction value
Shares: +1,000,000
Change %
Price
Shares after: 1,000,000
Date: 13 Feb 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 0
Exercise price
Footnotes: F2, F3, F4, F5

MYNZ transaction Derivative

Series B Preferred Shares

Award

Transaction value
Shares: +1,000,000
Change %
Price
Shares after: 1,000,000
Date: 13 Feb 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 0
Exercise price
Footnotes: F2, F3, F4, F5

MYNZ transaction Derivative

Series C Preferred Shares

Award

Transaction value
Shares: +1,000,000
Change %
Price
Shares after: 1,000,000
Date: 13 Feb 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 0
Exercise price
Footnotes: F2, F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

No ordinary shares are beneficially owned.

Footnote F2

On February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing promptly following effectiveness of the Stockholder Approval (as defined below), 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000.

Footnote F3

The First Closing Shares are not convertible into ordinary shares until Stockholder Approval is obtained. Following Stockholder Approval, each of the First Closing Shares will be convertible into 9 ordinary shares and each of the Second Closing Shares will be convertible into 225 ordinary shares, subject to certain ownership limitations. No Preferred Shares will be convertible until the Company's stockholders approve (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval").

Footnote F4

Following receipt by the Company of the Stockholder Approval, the Preferred Stock will be convertible into ordinary shares at the option of the Reporting Person for no additional consideration.

Footnote F5

Each class of Preferred Stock is perpetual and therefore has no expiration date.